Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis
Open Access
- 3 July 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 994
Abstract
Ewing sarcoma (EWS) is the second most common bone and soft tissue-associated malignancy in children and young adults. It is driven by the fusion oncogene EWS/FLI1 and characterized by rapid growth and early metastasis. We have previously discovered that the mRNA binding protein IGF2BP3 constitutes an important biomarker for EWS as high expression of IGF2BP3 in primary tumors predicts poor prognosis of EWS patients. We additionally demonstrated that IGF2BP3 enhances anchorage-independent growth and migration of EWS cells suggesting that IGF2BP3 might work as molecular driver and predictor of EWS progression. The aim of this study was to further define the role of IGF2BP3 in EWS progression. We demonstrated that high IGF2BP3 mRNA expression levels correlated with EWS metastasis and disease progression in well-characterized EWS tumor specimens. EWS tumors with high IGF2BP3 levels were characterized by a specific gene signature enriched in chemokine-mediated signaling pathways. We also discovered that IGF2BP3 regulated the expression of CXCR4 through CD164. Significantly, CD164 and CXCR4 colocalized at the plasma membrane of EWS cells upon CXCL12 stimulation. We further demonstrated that IGF2BP3, CD164, and CXCR4 expression levels correlated in clinical samples and the IGF2BP3/CD164/CXCR4 signaling pathway promoted motility of EWS cells in response to CXCL12 and under hypoxia conditions. The data presented identified CD164 and CXCR4 as novel IGF2BP3 downstream functional effectors indicating that the IGF2BP3/CD164/CXCR4 oncogenic axis may work as critical modulator of EWS aggressiveness. In addition, IGF2BP3, CD164, and CXCR4 expression levels may constitute a novel biomarker panel predictive of EWS progression.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Fondazione Guido Berlucchi
This publication has 50 references indexed in Scilit:
- CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axisMolecular Cancer, 2013
- Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's SarcomaMolecular Endocrinology, 2012
- Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancerOncogene, 2012
- Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocolAnnals of Oncology, 2010
- Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIPCell, 2010
- CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesisJournal of Clinical Investigation, 2010
- Overcoming Resistance to Conventional Drugs in Ewing Sarcoma and Identification of Molecular Predictors of OutcomeJournal of Clinical Oncology, 2009
- Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord blood CD133+ cellsBlood, 2006
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001